<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04297592</url>
  </required_header>
  <id_info>
    <org_study_id>201912215</org_study_id>
    <nct_id>NCT04297592</nct_id>
  </id_info>
  <brief_title>Antibiotic Prophylaxis in High-Risk Arthroplasty Patients</brief_title>
  <official_title>Antibiotic Prophylaxis in High-Risk Arthroplasty Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Iowa</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Iowa</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the effectiveness of a 7-day course of an oral, prophylactic antibiotic on the
      incidence of periprosthetic joint infection and wound complications following primary total
      hip and knee arthroplasty in a high-risk patient population.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this research study is to investigate whether a 7-day course of an oral,
      prophylactic antibiotic following elective, primary total hip and knee arthroplasty
      effectively decreases the risk of periprosthetic joint infection or wound complications
      following surgery in a patient population that is high-risk for these complications. Patient
      with one or more of the following risk factors are considered high-risk for periprosthetic
      joint infection and/or wound complications: body mass index over 35kg/m^2, diagnosis of
      diabetes, chronic kidney disease, active tobacco user, nasal colonization of
      methicillin-resistant Staphylococcus aureus and/or methicillin-sensitive Staphylococcus
      aureus, or autoimmune/inflammatory disease.

      Study participants will be randomized to either a 7-day course of an oral, prophylactic
      antibiotic following surgery or no additional antibiotic. All other standard perioperative
      total joint arthroplasty care will remain the same for both groups, including perioperative
      intravenous antibiotics. Outcomes assessed will include surgical wound complications
      occurring within 90-day of surgery and periprosthetic joint infection occurring within 90-day
      and 1-year of surgery.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2020</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">May 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Periprosthetic joint infections</measure>
    <time_frame>Within 90-days primary hip or knee arthroplasty</time_frame>
    <description>Defined by Musculoskeletal Infection Society (MSIS) criteria</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Periprosthetic joint infections</measure>
    <time_frame>Within 1-year of primary hip or knee arthroplasty</time_frame>
    <description>Defined by Musculoskeletal Infection Society (MSIS) criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Wound complication</measure>
    <time_frame>Within 90 days of primary hip or knee arthroplasty</time_frame>
    <description>Defined by at least one of the following: surgical wound dehiscence, skin necrosis at the surgical site, persistent surgical wound drainage (fluid extrusion from the operative site occurring beyond 72 hours from index surgery), superficial surgical site infection treated with new prescription of antibiotics or a change in study antibiotics but not meeting criteria for periprosthetic joint infection.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Infections Joint Prosthetic</condition>
  <condition>Overweight or Obesity</condition>
  <condition>MSSA Colonization</condition>
  <condition>MRSA</condition>
  <condition>Chronic Kidney Diseases</condition>
  <condition>Diabetes</condition>
  <condition>Autoimmune Diseases</condition>
  <condition>Inflammatory Disease</condition>
  <condition>Tobacco Use</condition>
  <arm_group>
    <arm_group_label>Group A - antibiotic group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will be given 7-days of an oral antibiotic (either cephalexin or doxycycline) to be started after completion of standard perioperative intravenous antibiotics following primary hip or knee arthroplasty</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B - no additional antibiotic</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No antibiotics will be prescribed following standard perioperative IV antibiotics following primary hip or knee arthroplasty.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cephalexin Oral Tablet</intervention_name>
    <description>Default oral antibiotic option for participants in Group A.</description>
    <arm_group_label>Group A - antibiotic group</arm_group_label>
    <other_name>Keflex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxycycline Hyclate</intervention_name>
    <description>Oral antibiotic option for participants in Group A if they have preoperative nasal colonization of methicillin-resistant Staphylococcus aureus, allergy to cephalosporins or a creatinine clearance less than 60 mL/min.</description>
    <arm_group_label>Group A - antibiotic group</arm_group_label>
    <other_name>Vibramycin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Undergoing elective, primary total hip or total knee arthroplasty

          -  Between the ages of 18-99

          -  Has one or more of the following high risk criteria: body mass index (BMI) greater
             than 35kg/m^2, diagnosis of diabetes, active tobacco user, chronic kidney disease
             (estimated glomerular filtration (eGFR) &lt; 60 mL/min/1.73 m2), nasal colonization of
             MRSA and/or MSSA or autoimmune/inflammatory disease.

        Exclusion Criteria:

          -  Younger than 18 years old

          -  Undergoing a revision hip or knee arthroplasty

          -  Will have a subsequent total joint arthroplasty performed within 12 weeks of study
             enrollment

          -  History of clostridium difficile colitis

          -  Undergoing non-elective procedure

          -  Hemiarthroplasty

          -  Unicompartmental knee arthroplasty

          -  Simultaneous bilateral total hip or knee arthroplasty

          -  Pregnant

          -  Unable to provide written consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicholas Bedard, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Iowa Hospitals &amp; Clinics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lauren Keitel, BS</last_name>
    <phone>(319) 467-7128</phone>
    <email>lauren-keitel@uiowa.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nicholas Bedard, MD</last_name>
    <phone>(319) 678-7947</phone>
    <email>nicholas-bedard@uiowa.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Iowa Hospitals &amp; Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Lauren Keitel, BS</last_name>
      <phone>319-467-7128</phone>
      <email>lauren-keitel@uiowa.edu</email>
    </contact>
    <investigator>
      <last_name>Nicholas A Bedard, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Inabathula A, Dilley JE, Ziemba-Davis M, Warth LC, Azzam KA, Ireland PH, Meneghini RM. Extended Oral Antibiotic Prophylaxis in High-Risk Patients Substantially Reduces Primary Total Hip and Knee Arthroplasty 90-Day Infection Rate. J Bone Joint Surg Am. 2018 Dec 19;100(24):2103-2109. doi: 10.2106/JBJS.17.01485.</citation>
    <PMID>30562290</PMID>
  </reference>
  <reference>
    <citation>Li B, Webster TJ. Bacteria antibiotic resistance: New challenges and opportunities for implant-associated orthopedic infections. J Orthop Res. 2018 Jan;36(1):22-32. doi: 10.1002/jor.23656. Epub 2017 Aug 11.</citation>
    <PMID>28722231</PMID>
  </reference>
  <reference>
    <citation>Kurtz SM, Lau E, Watson H, Schmier JK, Parvizi J. Economic burden of periprosthetic joint infection in the United States. J Arthroplasty. 2012 Sep;27(8 Suppl):61-5.e1. doi: 10.1016/j.arth.2012.02.022. Epub 2012 May 2.</citation>
    <PMID>22554729</PMID>
  </reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>March 3, 2020</study_first_submitted>
  <study_first_submitted_qc>March 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 5, 2020</study_first_posted>
  <last_update_submitted>April 2, 2020</last_update_submitted>
  <last_update_submitted_qc>April 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Iowa</investigator_affiliation>
    <investigator_full_name>Nicholas Bedard</investigator_full_name>
    <investigator_title>Dr. Nicholas Bedard, MD</investigator_title>
  </responsible_party>
  <keyword>total hip arthroplasty</keyword>
  <keyword>total knee arthroplasty</keyword>
  <keyword>hip replacement</keyword>
  <keyword>knee replacement</keyword>
  <keyword>periprosthetic joint infection</keyword>
  <keyword>prophylaxis</keyword>
  <keyword>antibiotics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Autoimmune Diseases</mesh_term>
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxycycline</mesh_term>
    <mesh_term>Cephalexin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

